AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

Video

In Partnership With:

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Related Videos
Debu Tripathy, MD
Parul N Barry, MD,
Ramez Kouzy, MD, MD Anderson
Elias Jabbour, MD
A panel of 4 experts on colorectal cancer
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Related Content
FDA

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024
Article
Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

FDA Approval Insights: Ponatinib in Ph+ ALL

April 8th 2024
Podcast
OncLive On Air Podcast Recap

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024
Article
John H. Strickler, MD, associate professor, medicine, member, the Duke Cancer Institute; Michael Leung, PharmD, BCOP, clinical pharmacy specialist, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center; Arvind N. Dasari, MD, MS, associate professor, the Department of GI Medical Oncology, the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Margot O’Neill, PA-C, MHS, physician assistant, oncology, the Duke Cancer Institute

CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

March 25th 2024
Podcast
Lung Cancer

Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC

May 10th 2024
Article
FDA

SNB-101 Receives FDA Fast Track Designation for SCLC

May 10th 2024
Article